AU615715B2

AU615715B2 – Receptor protein for human b cell stimulatory factor-2
– Google Patents

AU615715B2 – Receptor protein for human b cell stimulatory factor-2
– Google Patents
Receptor protein for human b cell stimulatory factor-2

Download PDF
Info

Publication number
AU615715B2

AU615715B2
AU28720/89A
AU2872089A
AU615715B2
AU 615715 B2
AU615715 B2
AU 615715B2
AU 28720/89 A
AU28720/89 A
AU 28720/89A
AU 2872089 A
AU2872089 A
AU 2872089A
AU 615715 B2
AU615715 B2
AU 615715B2
Authority
AU
Australia
Prior art keywords
ser
pro
leu
ala
val
Prior art date
1988-01-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired

Application number
AU28720/89A
Other versions

AU2872089A
(en

Inventor
Tadamitsu Kishimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1988-01-22
Filing date
1989-01-23
Publication date
1991-10-10
Family has litigation

First worldwide family litigation filed
litigation
Critical
https://patents.darts-ip.com/?family=27454721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU615715(B2)
“Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1989-01-23
Application filed by Individual
filed
Critical
Individual

1989-07-27
Publication of AU2872089A
publication
Critical
patent/AU2872089A/en

1991-10-10
Application granted
granted
Critical

1991-10-10
Publication of AU615715B2
publication
Critical
patent/AU615715B2/en

2009-01-23
Anticipated expiration
legal-status
Critical

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C12N15/09—Recombinant DNA-technology

C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons

C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P35/00—Antineoplastic agents

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P37/00—Drugs for immunological or allergic disorders

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C12N15/09—Recombinant DNA-technology

C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

C12N5/10—Cells modified by introduction of foreign genetic material

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K38/00—Medicinal preparations containing peptides

Abstract

Isolated receptor proteins for human B cell stimulating factor-2 are capable of specifically binding to human B cell stimulating factor-2. DNA coding for the above-mentioned receptor protein, expression vectors containing the above-mentioned DNA, host organisms transformed with the above-mentioned expression vector, a process for production of the receptor protein comprising culturing the host organisms in a medium to produce the receptor protein and recovering the receptor protein from the culture, and an antibody reacting with the protein are also disclosed.

Description

615715 CO0M P LE TE SPECIFICATION FOR OFFICE USE kpplication Number: Lodged: Complete Specification Priority: Class Int. Class Lodged: Accepted: Published: r0M T’hii document conta ins the amendmnts allowed Undri Section 83 by the Supezvising Examilner onI ant is correct tot printing 0900 0 0 0904 04 0 0 00 o 00 0 0 0 OoO 0 00 00 0 0 00 00 0 0 0 0 0~ 0000 0 0 0 00 0 0 00 0 0 0 0 OQ 0 00000 0 0 00 00 00 0 0 0 00 0 0 0 0 4 00 Related Art: TO BE COMPLETED BY APPLICANT Name of Applicant: Address of Applicant: Actual Inventor: Address for Service: TADAMITSU KISH-IMOTO 5-31, Nakanocho 3–chome, Tondabayashi-shi, Osaka, Japan.
Tadamitsu KISHIMOTO SMITH SHELSTON BEADLE 207 Riversdale Road Box 410) Hawthorn, Victoria, Australia Complete Specification for the invention entitled: RECEPTOR PROTEIN FOR HUMAN BE CELL STIMILATORY The following statement is a full description of this invention, including the best method of performing it known to me: Page 1 Our Ref: MW:TNB:WB:9tadamit.pl
A
TYS-6615 la 1. Field of the Invention The present invention relates to a receptor protein for a human B cell stimulatory factor-2 (hereinafter abbreviated as BSF2 receptor), a DNA sequence coding for the BSF2 receptor, and a process for the production of the BSF2 receptor using genetic engineering techniques.
0 2. Description of the Related Art 0L 0 10 The B-cell stimulatory factor-2 (BSF2) is o believed to be a factor which differentiates B-cells to o antibody-producing cells. Recently, a cDNA coding for o BSF2 was isolated, and on the basis of information 0 00 o0 relating to the DNA sequence and information relating to 0 15 the partial amino acid sequence of the purified BSF2, the BSF2 was defined as a protein comprising 184 amino acid residues accompanied by a signal peptide consisting o of 28 amino acid residues Hirano, K. Yoshida and H.
0 o Harada et al, Nature, 324 73-76, 1986).
.oooo 20 According to recent findings, the BSF2 is believed to induce B cells to produce antibodies; to stimulate the growth of hybridoma, plasmacytoma, myeloma 0 and the like, to induce the expression of HLA class I O antigens; to induce acute phase proteins on hepatocyte; 0 00 and induce neuraxons Kishimoto and T. Hirano, Ann.
Rev. Immunol. 6. 485, 1985). As seen from the above, the BSF2 has various important physiological activities, and is extensively related to cell growth (Hirano et al, Summary of the 17th conference of Japan Immunology Association, pp 91,1987).
On the other hand, Iirano et al., Proc. Natl.
Acad. Sci. Vol 84, pp 228, 1987, reported the possibility that an abnormal production of BSF2 is an 2 etiology of an immune disorder in such diseases as cardiac mixoma, cervical cancer, myeloma, chronic articular rheumatism, Castleman’s syndrome, and the like. Accordingly, an inhibitor of the BSF2 would be promising as a diagnostic, prophylactic or therapeutic agent for the above-mentioned diseases.
T. Taga et al., J. Exp. Med. 196, pp 967, 1987, analyzed a BSF2 receptor which is found on a cell membrane and specifically linked to the BSF2, and reported the number there on a cell and the binding constant with BSF2. The BSF2 receptor released from o° o cell surface is promising as diagnostic, prophylactic 000 and therapeutic agents and the like, and therefore, 0 0 15 there is great interest in the progress of research into 00 So o the BSF2 receptor.
0 0o To enable further progress in the research 0 into the BSF2 receptor and the development of diagnostic, prophylactic and therapeutic agents, the availability of a large amount of purified BSF2 receptor o is essential, although the receptor can be produced in vivo in only a very small amount.
For the production of proteins, such as “0 00 the BSF2 receptor, present in a very small amount in an organism, a genetic engineering technique also known as genetic manipulation is used. In this 00 00 0 technique, a DNA sequence coding for a desired protein is cloned, the cloned DNA sequence is operatively linked with control DNA sequences such as a promoter, and the DNA sequence is inserted into a vector to construct an expression vector, which is then used to transform host cells. The transformant is cultured to produce the desired protein. To use such a genetic engineering procedure to produce a target protein, it is necessary to obtain a DNA sequence coding for the target protein. However, the gene coding for the BSF2 receptor has not yet been cloned.
-3- SUMMARY OF THE INVENTION Accordingly, the present invention provides a BSF2 receptor protein, a DNA sequence coding for the BSF2 receptor protein, vectors containing the DNA sequence, host cells transformed with the vector, and a process for the production of the BSF2 receptor using the trans formant.
More specifically, the present invention provides an isolated receptor protein for human B cell stimulatory factor-2, capable of specifically binding to the human B cell stimulatory factor-2.
The present invention also provides a DNA coding for the above-mentioned receptor protein.
The present invention further provides expression 0 99 aq 15 vectors containing the above-mentioned DNA.
a 0.9The present invention, moreover, provides host organisms transformed with the above-mentioned expression vector.
In addition, the present invention provides a process for the production of the receptor protein, comprising culturing the host organisms in a medium to produce the receptor protein and recovering the receptor protein from the culture.
Further, the present invention provides an antibody specifically reacting with the receptor protein.
Moreover, the present invention provides a hybridoma producing a monoclonal antibody specifically 00~ reacting with the receptor protein.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 represents a graph of fluorescence intensity versus cell frequency in an experiment wherein cells are stained with fluorescence via BSF2-biotin-avidin. In the figure, represents a result obtained with cells transfected with a negative vector, represents a result obtained with cell~s transfected with a vector containing the present cDNA, and (C) represents a result obtained by treating the above- -4 4 mentioned positively transfected cell with biotinated BSF2 in the presence of an excess amount of BSF2; Figure 2 represents a restriction enzyme cleavage map for a cDNA containing a DNA sequence coding for the BSF2 receptor, derived from a monocyte U937 cell line in the Example, wherein a box with oblique lines shows a region from a translation initiation codon ATG to a translation stop codon
TAG;
G
0 Figures 3-1 to 3-5 represent a nucleotide sequence of DNA containing a region coding for the BSF2 receptor derived from a monicyte U937 cell line, and an amino o acid sequence of the BSF2 receptor presumed from the i o ‘nucleotide sequence. In the sequence, the single So 15 underline part represents a hydrophobic region at the N-terminal, and the double underline part represents a hydrophobic region at the C-terminal; 00o Figure 4 represents a result of a Northern blotting analysis, wherein the presence or absence of a hybridigation signal conforms to the presence or absence Sof the BSF2 receptor from all lines.
oFig. 5 represents a process for the construction of plasmid pABSF2RI.1; Fig. 6 represents a process for the construction of plasmid Fig, 7 is a graph showing fluorescence intensity o versus cell frequency in an experiment for COP cells transfected with plasmid pBSF2R.236: The meanings of A, B and C are the same as in Fig. 1; Fig. 8 is a graph showing fluorescence intensity versus cell frequency in an experiment for COP cells 4 transfected with plasmid pABSF2RI.1: The meanings of A, B and C are the same as in Fig. 1; Fig. 9 is a graph showing fluorescence intensity versus cell frequency in an experiment for COP cells transfected with plasmid pABSF2RII.5: The meanings of A, B and C are the same as in Fig. 1; 18 opportunity to develop prophilactic and therapeutic pharmaceuticals as well as diagnostic agents relating to deseases or disorders associated with an abnormal production of the BSF2. Moreover, the availability of the BSF2 receptor protein in a purified form will A &a It wer o 4- e +kAh s e 4- A4f ft 1I- I _t 5 Figs. 10A and B represent a process for the construction of plasmid phBABSF2R, and structure thereof; Fig. 11 is a graph showing that a protein produced by plasmid phBABSF2R specifically binds to BSF2; Fig. 12 represents a process for the construction of plasmid pSVL345; Fig. 13 represents a process for the construction of plasmid pSVL324; Fig. 14 shows a results of the detection by enzyme immuno assay of a soluble BSF2 receptor protein in a supernatant from a culture of COS-1 cells transfected with plasmid pSVL345 or pSVL324; l”* o Fig. 15 is a graph showing a specific binding to So 15 BSF2 of products in a supernatant from a culture of o COS-1 cells transfected with plasmid pSVL345 or pSVL324; o Fig. 16 is a graph showing a competitive inhibition 0 125 0 o of cold BSF-2 and I-BSF2 for the binding to product in a supernatant from a culture of COS-1 cells transfected with plasmic SVL345 or pSVL324; .0″S Fig. 17 is a graph showing that product in a COO supernatant from a culture of COS-1 cells transfected with plasmid pSVL345 or pSVL324 binds to both the MT18 4A a antibody and BSF2; Fig. 18 represents an electrophoresis pattern wherein the product in a supernatant from a culture of S COS-1 cells transfected with plasmid pSVL345 or pSVL324 and a lysate of BSF2 receptor-producer U266 cells as a control were separated by SDS-PAGE and detected with an MT18 antibody; Fig. 19 schematically represents structures of the BSF2 receptor protein and shortened analogues thereof; and Fig, 20 is a graph showing fluorescence intensity versus cell frequency, showing that the MT18 antibody binds only to cells producing the BSF2 receptor.
Wherein A represents a result for JURKAT cells which do 6 not produce the BSF2 receptor, and B represents a result for NJBC8 cells which produce the BSF2 receptor.
DESCRIPTION OF THE PREFERRED EMBODIMENTS BSF2 receptor The present invention relates to a human receptor for a B cell stimulatory factor-2 (BSF2 receptor) in an isolated form. The BSF2 receptor is a protein which specifically binds to the human B cell stimulatory factor-2, and is originally produced in vivo and is present on a cell membrane. The BSF2 receptor of the present invention includes any protein with an abovementioned biological activity. In one embodiment, the BSF2 receptor protein of the present invention has the 0o0 0 0 S a 0 oo o o’ 0 00 0 00 00 0 0 0 00 0 0 00 o 0 S 0 O 00 S o 0 0 a 0 A 0 00 a 0 0 0 0 following amino acid (N-terminal) Met Leu Ala Val Ala Ala Pro Gly Ala Gin Glu Val Gly Asp Ser Val Glu Asp Asn Ala Ala Ala Gly Ser Arg Arg Leu Leu Gly Asn Tyr Ser Thr Val His Leu Gin Leu Ser Cys Val Cys Glu Trp Thr Lys Ala Val Pro Ala Glu Asp Glu Ser Gln Lys Gly Asp Ser Ser Set Ser Val Gly Gin Gly Cys Gly lie Thr Val Thr Set Val Thr Trp Phe Tyr Arg Leu Arg Ser Lys Thr Gin His His Cys sequence Gly Cys Ala Leu Ala Ala Leu Ala Ala Arg Gly Val Thr Leu Thr Cys Thr Val His Trp His Pro Ser Arg Leu Arg Ser Val Cys Tyr Arg Ala Leu Val Asp Val Phe Arg Lys Ser Gly Pro Arg Ser Leu Leu Val Arg Phe Gln Glu Pro Phe Ser Cys Gin Phe Tyr lie Val Ser Lys Phe Ser lie Leu Gin Pro Ala Val Ala Arg Gin Asp Pro His Arg Phe Glu Leu Phe Thr Thr Trp Val lie His Asp Leu Ala Ala Leu Leu Pro Arg Arg Cys Pro Leu Thr Ser Leu Pro Pro Gly Val Glu Pro Val Leu Arg Lys Pro Trp Ala Gly Met Gly Gin Leu His Asp Ser Gly Arg Pro Ala Gly Pro Pro Glu Glu Pro Pro Leu Ser Asn Val Thr Pro Ser Leu Thr Lys Phe Gin Asn Ser Cys Gin Tyr Ser Gin Leu Ala Val Pro Glu Ser Met Cys Val Ala Lys Thr Gin Thr Phe Asp Pro Pro Ala Asn Asn Pro Arg Trp Leu Ser Trp Asn Ser Ser Arg Tyr Arg Ala Glu Met Val Lys Asp Leu Ala Trp Ser Gly Leu w -t 7 Arg His Val Val Gin Leu Arg Ala Gin Glu Glu Phe Gly Gin Gly Glu Trp Ser Glu Trp Ser Pro Glu Ala Met Gly Thr Pro Trp Thr Glu Ser Arg Ser Pro Pro Ala Glu Asn Glu Val Ser Thr Pro Met Gin Ala Leu Thr Thr Asn Lys Asp Asp Asp Asn Ile Leu Phe Arg Asp Ser Ala Asn Ala Thr Ser Leu Pro Val Gln Asp Ser Ser Ser Val Pro Leu Pro Thr Phe Leu Val Ala Gly Gly Ser Leu Ala Phe Gly Thr Leu Leu Cys Ile Ala Ile Val Leu Arg Phe Lys Lys Thr Trp Lys Leu Arg Ala Leu Lys Glu Gly Lys Thr Ser Met His Pro Pro Tyr Ser Leu Gly Gin Leu Val Pro Glu Arg Pro Arg Pro Thr Pro Val Leu Val Pro Leu Ile Ser Pro Pro Val Ser Pro Ser Ser Leu Gly Ser Asp Asn Thr Ser Ser His Asn Arg Pro Asp Ala Arg Asp Pro Arg Ser Pro Tyr Asp Ile Ser Asn Thr Asp Tyr Phe Phe Pro Arg (C-terminal) wherein Ala represents L-alanine, Arg represents I L-arginine, Asn represents L-asparagine, Asp represents oo L-aspartic acid, Cys represents L-cysteine, Gin 0 0 represents L-glutamine, Glu represents L-glutamic acid, So’c 20 Gly represents glycine, His represents L-histidine, Ile represents L-isoleucine, Leu represents L-leucine, Lys represents L-lysine, Met represents L-methionine, Phe o represents L-phenylalanine, Pro represents L-proline, Ser represents L-serine, Thr represents L-threonine, Trp o 25 represents L-tryptophan, Tyr represents L-threosine, Trp represents L-tryptophan, Tyr represents L-tyrosine, and Val represents L-valine.
The amino acid sequence of the present BSF2 eo o. receptor protein represented by the sequence t S° 3~ consists of 468 amino acid residues, and contains two hydrophobic regions, an N-terminal hydrophobic region from the second leucine to the 22nd proline, and C-terminal hydrophobic region from the 362nd valine to the 386th leucine. The former is expected to be a signal peptide region and the latter to be a region responsible for the penetration of the protein through a cell membrane (membrane penetration region). Note, a aa a a a 9017 9a a0 a a a a ro -a a a ao a o i a’ 9 a O 8 within the present invention, a region between the signal peptide region and the membrane penetration region is designated as an “extracellular protein region”, and a region of a C-terminal from the membrane penetration region is designated as an “intracellular protein region”.
The BSF2 receptor of the present invention includes, in addition to the protein having the abovementioned particular amino acid sequence, any proteins or polypeptides capable of specifically binding to the BSF2. For example, modified proteins or polypeptides wherein one or more than one amino acid residue in the above-mentioned amino acid is replaced by a different amino acid residue; one or more than one amino acid residue is deleted, or one or more than one amino acid residue is added to the above-mentioned amino acid sequence, while maintaining the biological activity of the native BSF2 receptor. For example, proteins wherein an amino acid sequence and/or an amino acid residue 20 excluding a region in the above-mentioned amino acid sequence, which relates to binding with the BSF2, are deleted or replaced with another amino acid sequence and/or an amino acid residue, and proteins wherein an amino acid sequence and/or an amino acid residue are 25 added to the above-mentioned amino acid sequence at the N-terminal and/or C-terminal thereof. Moreover, the present BSF2 receptor may be a fusion protein wherein any one of the above-mentioned proteins is fused with another protein such as a human growth hormone, or a 30 fragment thereof.
For example, the biologically active modified proteins wherein amino acid residues in the abovementioned amino acid sequence are deleted, include proteins wherein amino acid residues near the N-terminal in the amino acid sequence are deleted. An embodiment of such a modified protein has an amino acid sequence wherein an amino acid sequence from the 28th i a. 1 9 amino acid to the 109th amino acid is deleted from the amino acid sequence and represented by the following amino acid sequence (II): o o o 0 o on 00 0 0 0 0 0 o0 0 00o (N-terminal) Met Leu Ala Val Ala Ala Pro Gly Ala Val Asp Val Phe Arg Lys Ser Gly Pro Arg Ser Leu Leu Val Arg Phe Gln Glu Pro Phe Ser Cys Gln Phe Tyr Ile Val Ser Lys Phe Ser Ile Leu Gln Pro Ala Val Ala Arg Gln Asp Pro His Arg Phe Glu Leu Phe Thr Thr Trp Val Ile His Asp Gln Leu Arg Ala Ser Glu Trp Ser Glu Ser Arg Ser Pro Met Gln Ala Ile Leu Phe Arg Val Gln Asp Ser Val Ala Gly Gly Ile Ala Ile Val Arg Ala Leu Lys Gly Cys Ala Leu Leu Ala Ala Leu Leu Ala Ala Leu Ala Pro Arg Arg Cys Pro Pro Pro Glu Glu Pro Gln Leu Ser Cys Pro Leu Ser Asn Val Val Cys Glu Trp Thr Pro Ser Leu Thr Thr ,ys Ala Val Lys Phe Gln Asn Ser Pro Ala Glu Asp Cys Gln Tyr Ser Gln Glu Ser Gln Lys Leu Ala Val Pro Glu Gly Asp Ser Ser Ser Met Cys Val Ala Ser Ser Val Gly Lys Thr Gln Thr Phe Gln Gly Cys Gly Asp Pro Pro Ala Asn Ile Thr Val Thr Asn Pro Arg Trp Leu Ser Val Thr Trp Ser Trp Asn Ser Ser Phe Tyr Arg Leu Arg Tyr Arg Ala Glu Arg Ser Lys Thr Met Val Lys Asp Leu Gln His His Cys Ala Trp Ser Gly Leu Arg His Val Val Gln Glu Glu Phe Gly Gln Gly Glu Trp Pro Glu Ala Met Gly Thr Pro Trp Thr Pro Pro Ala Glu Asn Glu Val Ser Thr Leu Thr Thr Asn Lys Asp Asp Asp Asn Asp Ser Ala Asn Ala Thr Ser Leu Pro Ser Ser Val Pro Leu Pro Thr Phe Leu Ser Leu Ala Phe Gly Thr Leu Leu Cys Leu Arg Phe Lys Lys Thr Trp Lys Leu Glu Glv Lvs Thr Ser Met His Pro Pro 0 0 So o o f o 0 oo 0o 0 o o 0 o0 Tyr Thr Pro Arg Ser Leu Gly Gln Pro Val Leu Val Ser Ser Leu Gly Pro Asp Ala Arg Leu Val Pro Pro Leu Ile Ser Asp Asn Asp Pro Arg Glu Arg Pro Arg Pro Ser Pro Pro Val Ser Thr Ser Ser His Asn Ser Pro Tyr Asp Ile Arg. Ser Asn Thr Asp Tyr Phe Phe Pro (C-terminal) Further, other types of the biologically active modified proteins wherein amino acid residues in the i li ‘Jk 1 10 above-mentioned amino acid sequence are deleted, include proteins wherein amino acid residues of the C-terminal portion in the amino acid sequence are deleted. An embodiment of such modified protein has an amino acid sequence wherein an amino acid sequence from the 324th amino acid to the 468th amino acid are deleted, and represented by the following amino acid sequence (III): (N-terminal) a 0 00 0 00 0 0 00 0 O 4 O t 00 S0 4 0 00 9 Go o 0 Met Leu Ala Ala Ala Pro Ala Gin Glu Gly Asp Ser Glu Asp Asn Ala Ala Gly Arg Arg Leu Gly Asn Tyr Thr Val His Gin Leu Ser Val Cys Glu Thr Lys Ala Pro Ala Glu Glu Ser Gln Gly Asp Ser Ser Ser Val Gin Gly Cy,; Ile Thr VAl Ser Val Thr Phe Tyr Arg Arg Ser Lys Gln His His Arg His Val Gln Gly Glu Thr Pro Trp Val Gly Cys Ala Gly Ala Ala Leu Val Ala Arg Gly Val Thr Leu Thr Ala Thr Val His Ser His Pro Ser Leu Leu Arg Ser Ser Cys Tyr Arg Leu Leu Val Asp Cys Phe Arg Lys Trp Gly Pro Arg Val Leu Leu Val Asp Phe Gin Glu Lys Phe Ser Cys Ser Phe Tyr Ile Gly Ser Lys Phe Gly Ile Leu Gin Thr Ala Val Ala Trp Gin Asp Pro Leu Arg Phe Glu Thr Phe Thr Thr Cys Val Ile His Val Gin Leu Arg Trp Ser Glu Trp Thr Glu Ser Arg Leu Ala Val Cys Trp Arg Val Ala Val Ser Ser Arg Pro Gin Val Ser Pro Arg His Leu Trp Asp Ala Ser Ser Leu Ala Pro Arg Leu Thr Pro Gly Val Leu Trp Ala Gln Leu Gly Arg Pro Pro Pro Leu Thr Pro Lys Phe Cys Gin Leu Ala Ser Met Lys Thr Asp Pro Asn Pro Ser Trp Arg Tyr Met Val Ala Trp Gin Glu Pro Glu Ala Arg Ser Val Arg Gly His Pro Glu Ser Ser Gin Tyr Val Cys Gin Pro Arg Asn Arg Lys Ser Glu Ala Leu Cys Leu Glu Lys Met Asp Ala Glu Asn Leu Asn Ser Pro Val Thr Ala Trp Ser Ala Asp Gly Phe Met Leu Pro Pro Pro Pro Gly Ser Gly Pro Val Thr Ser Gin Glu Ala Phe Asn Leu Ser Glu Leu Leu Gly Gly Pro Pro Val.
(C-terminal) Another embodiment of the modified protein wherein a C-terminal portion of the amino acid sequence is P;i 11 deleted, has the following amino acid sequence (IV): (N-terminal) Met Leu Ala Val Gly Cys Ala Ala Pro Gly Ala Ala Ala Gln Glu Val Ala Arg Gly Asp Ser Val Thr Leu Glu Asp Asn Ala Thr Val Ala Ala Gly Ser His Pro Arg Arg Leu Leu Leu Arg Gly Asn Tyr Ser Cys Tyr Thr Val His Leu Leu Val Gin Leu Ser Cys Phe Arg Val Cys Glu Trp Gly Pro Thr Lys Ala Val Leu Leu Pro Ala Glu Asp Phe Gln Glu Ser Gin Lys Phe Ser Gly Asp Ser Ser Phe Tyr Ser Ser Val Gly Ser Lys Gin Gly Cys Gly Ile Leu Ile Thr Val Thr Ala Val Ser Val Thr Trp Gin Asp Phe Tyr Arg Leu Arg Phe Arg Ser Lys Thr Phe Thr Gin His His Cys Val Ile Arg His Val Val Gin Leu Gin Gly Glu Trp Ser Glu Thr Pro Trp Thr Glu Ser Glu Val Ser Thr Pro Met Ala Leu Leu Ala Leu Ala Pro Arg Gly Val Leu Thr Thr Cys Pro Cly His Trp Val Leu Ser Arg Trp Ala Ser Val Gln Leu Arg Ala Gly Arg Asp Val Pro Pro Lys Ser Pro Leu Arg Ser Thr Pro Val Arg Lys Phe Glu Pro Cys Gln Cys Gin Leu Ala Ile Val Ser Met Phe Ser Lys Thr Gin Pro Asp Pro Ala Arg Asn Pro Pro His Ser Trp Glu Leu Arg Tyr Thr Trp Met Val His Asp Ala Trp Arg Ala Gin Gl’i Trp Ser Pro Glu Arg Ser Pro Pro Gin Ala Ler Thr 0 0 0 B O 0 Q 0 0 Ala Leu Leu Arg Cys Pro Ser Leu Pro Val Glu Pro Arg Lys Pro Gly Met Gly His Asp Ser Pro Ala Gly Glu Glu Pro Ser Asn Val Ser Leu Thr Gin Asn Ser Tyr Ser Gin Val Pro Glu Cys Val Ala Gin Thr Phe Pro Ala Asn Arg Trp Leu Asn Ser Ser Arg Ala Glu Lys Asp Leu Ser Gly Leu Glu Phe Gly Ala Met Gly Ala Glu Asn Thr Asn Lys 0 0 a 0 0 08 Asp Asp Asp Asn Ile Leu.
(C-terminal) DNA sequence coding for BSF2 receptor DNA sequences of the present invention include those coding for any one of the above-mentioned BSF2 receptor proteins.
In an embodiment, the present DNA sequences are those coding for the amino acid sequence represented by the sequence Due to the degeneracy of codons, L _i I j 12 there may be many particular DNA sequences. The DNA sequence of the present invention can be prepared by any conventional procedure. For example, a nucleotide sequence of the present DNA can be designed according to the above-mentioned amino acid sequence, considering codons frequently used in a host cell which is chosen for the production of the BSF2 receptor protein and can be chemically synthesized. Alternatively, the desired DNA may be prepared from a genome of BSF2 receptor producing cells.
Most conveniently, however, a DNA fragment containing gene coding for the BSF2 receptor can be prepared as cDNA from the BSF2 receptor producing cells, such as the NK cell YT, monocyte cell line U937, myeloma cell line U266, B cell CESS. Namely, mRNA is extracted .oO” from cultured cells of any of the above-mentioned cells oo lines according to a conventional procedure, and a cDNA 0, olibrary is constructed on the basis of the mRNA.
o The cDNA library may be then screened using an o”o 20 oligonucleotide probe corresponding to a part of the above-mentioned sequence Alternatively, and preferably, according to the present invention, the cDNA 0 0 library can be screened without a probe. In this Ud 0 Soprocedure, the cDNA library is used to prepare vectors S 25 containing cDNA, which are then used to transform animal ;cells. The cells are then cultured, and the cultured cells are treated with a biotinated BSF2 preparation.
During this procedure, cells which have expressed the ao%\ BSF2 receptor bind the BSF2 moiety of the biotinated 30 BSF2. The treated cells are then treated with avidin conjugated with fluorescein isocyanate to react the biotin moiety fixed to the cells with the avidin moiety of the avidin-fluorescein isocyanate conjugate. Subsequently, cells which have expressed the BSF2 receptor, and therefore carry fluorescein isocyanate on their surface, are separated and selected by a cell sorter, The desired cDNA coding for the BSF2 receptor is then 9 i ft- A n.j ii ‘4
I
I
‘I
EE
2 0 00 00 000 0 60 06 0 o 66 40 0 6 00 06 13 extracted from the selected cells. An embodiment of a cDN’A thus obtained has the following sequence ATG CTG GCC GTC GCC GCG CCG GGA GCG CAG GAG GTG GGA GAC AGC GTG GAA GAC AAT GCC GCT GCA GGC TCC AGG AGG CTG CTG GGA AAC TAT TCA ACT GTG CAC TTG CAG CTC TCC TGC GTT TGT GAG TGG ACA AAG GCT GTG CCG GCC GAA GAC GAG TCC CAG AAkG GGA GAC AGC TCT AGT AGT GTC GGG CAG GGT TGT GGA ATC ACA GTC ACT AGT GTC ACC TGG TTC TAC AGA CTA CGG TCA AAG ACA CAG CAT CAC TGT AGG CAC GTG GTG CAA GGC GAG TGG ACG CCT TGG ACA GAG GTG TCC ACC GAC GAT GAT AAT ACA AGC CTC CCA CCC ACA TTC CTG ACG CTC*” CTC TGC ACG TGG AAG CTG ATG CAT CCG CCG AGG CCT CGA CCC CCA CCG GTG TCC
GGC
GCG
GCA
ACT
ACT
CAC
CTG
TGC
CTG
TTC
GGT
CTC
TTC
TTC
TTC
AGC
ATC
GCC
CAA
CGG
TTC
GTC
CAG
AGC
GAA
CCC
ATT
GTG
GTT
ATT
CGG
TAC
ACC
CCC
TGC
GCG
AGA
CTG
GTT
CCC
AGG
TAC
GTG
CGG
CCT
TTG
CAG
TCC
TAC
AAG
TTG
GTG
GAC
TTT
ACA
ATC
CTT
GAG
TCC
ATG
CTC
CAA
GCT
GCC
GCT
TCT
CCA
AGC
GCG
CTG
GGC
ACC
CAC
AGC
TCG
CGG
GAT
AAG
CGG
GTG
GAG
TGC
ATA
TTC
CAG
GCC
CCC
GAG
ACA
CAC
CGT
TGG
AGG
CAG
TTC
GAT
GGA
ATT
CTG
TTG
GTC
AGC
CTG
GCC
GTG
TGC
TGG
AGA
GTG
GCC
OTT
AGC
AGC
AGG
CCG
CAG
GTG
AGC
CCT
AGA
CAC
CTC
TGG
GAC
GCC
AGC
AGT
GCA
AGA
TCT
GG
OTT
AAG
GG
CTT
CTG
CTG OCT CCA AGG CTG ACC CCG GG GTG CTC T(GG GCT CAG CTC GGC CGC CCC CCC CCC CTC ACC CCA AAG TTT TGC CAG TTA OCA TCC ATG AAA ACT GAT CCG AAC CCC TCC TG AGA TAT ATO GTC GCC TG CAG GAG CCG GAG CCT CCA CTT ACT GAT TCT TCT TCA AGC CTG CTG AGO GAA GOC CAG OTO GTT CCT GGG TCT
GCC
CGC
AGT
GTA
AGG
GGC
CAC
CCA
GAG
AGC
TCC
CAG
TAT
GTC
TGC
CAA
CCT
CGC
AAC
CG
AAG
AGC
GAG
GCC
OCT
ACT
GCA
GTA
GCC
TTC
AAG
GTC
CTC
GAG
CTG
TGC
CTG
GAG
AAG
ATG
GAC
GCT
GAG
AAT
CTG
AAC
TCC
CCO
GTC
ACC
GCC
TGG
TCA
GCT
GAC
GGC
TTC
ATG
GAG
AAT
AAT
CCA
TTC
AAG
ACA
CCG
ATC
AAT
CTG
CCT
CCA
CCG
CCG
OGA
TCT
GGG
CCC
GTT
ACG
AGT
CAG
GAG
GCC
TTT
AAC
CTC
TCT
OAA
CTC
CTG
GGG
GGC
AAC
AAA
GCG
CTG
GGA
AAG
AGO
GAG
TCC
ACC
0000 0 00 00 0 0 60 06 0 O 00 6 440660 0 46 00 06 0 6 0 6* 6 6 44 6
A.
-14- TCG AGC CAC AAC CGA CCA GAT GCC AGG GAC CCA CGG AGC CCT TAT GAC ATC AGC AAT ACA GAC TAC TTC TTC CCC AGA.
(3′-terminal) The DNA sequence of the present invention includes, in addition to the above-mentioned sequence those wherein one or more than one nucleotide 1 in the above-mentioned sequence is replaced by other nucleotides, or wherein one or more than one codon is added to or deleted from the sequence still coding for a protein capable of binding to the BSF2.
For example, a DNA coding for a shortened or truncated BSF2 receptor protein can be prepared by cleaving the above-mentioned cDNA having the nucleotide sequence with an appropriate restriction enzyme to foO” delete a portion of the nucleotide sequence and reoo ligating the cleaved DNA fragments it necessary via an appropriate linker.
o’ For example, a vector containing the cDNA having 4 ft 0 20 the nucleotide sequence can be manipulated according to Example 6, to prepare a vector containing a DNA coding for a protein consisting of an amino acid sequence 1 to 123 and an amino acid sequence 343 to 468 of the above-mentioned amino acid sequence Simi- 25 larly, a vector containing a DNA coding for a prctein o na consisting of an amino acid sequence 1 to 27 and amino acid sequence 110 to 468 of the amino acid sequence (I) can be prepared.
\jO In another embodiments any nucleotide in the abovea 30 mentioned vector can be deleted or replaced by another J nucleotide by site-specific invitro-mutagenesis. In this manner, a translation stop codon can be introduced at any position of the cDNA coding for BSF2 receptor protein to obtain a DNA coding for any C-terminal truncated BSF2 receptor protein. For example, as shown in Example 11, a vector containing a DNA coding for a protein having an amino acid sequence 1 to 344 of the 2- f__il4-LIL–( II^I*YCI~LI*L~)CI 15 I 4 464 *4 44 4 44 4 r 4i 90 441 06 4 4 44 4 64C II 44O amino acid sequence is constructed. According to a similar procedure, a vector containing DNA coding for a protein having an amino acid sequence 1 to 323 of the amino acid sequence is constructed.
Next, the DNA, for example, cDNA, coding for the BSF2 receptor is linked with DNA sequences necessary for the expression of the BSF2 receptor in a host. Such DNA sequences include a promoter, start codon and stop codon of the transcription and translation, and are selected depending on the nature of the host used. Among the DNA sequences necessary for the expression, the promoter is important. A promoter which can be used as a bacterial host includes known promoters such as f-lactamase and lactose promoter, tryptophan promoter, and hybrid promoters derived therefrom. For a yeast host, for example, GAL4 promoter can be used.
In addition to the above-mentioned DNA sequences necessary for the expression of the BSF2 receptor, preferably another control sequence such as a ribosome 20 binding site is linked with the DNA coding for the BSF2 receptor.
The DNA sequence coding for the BSF2 receptor is linked with the above-mentioned DNA sequences necessary for the expression of the BSF2 receptor in a manner such that the DNA sequence coding for BSF2 receptor can be transcribed and transformed in a selected host under the control of the DNA sequences necessary for the expression of the BSF2. The linkage is usually carried out by ligation via cohesive ends or 30 blunt ends, preferably via cohesive ends, of the DNA sequences to be linked.
According to a preferable embodiment of the present invention, the BSF2 receptor protein is expressed as a fusion protein with a partner protein, such as a human growth hormone protein. In such a case, the 5′-end of the DNA sequence coding for the BSF2 receptor is ligated in a reading frame with the 3′-end of a DNA sequence i 16 coding for the partner protein, such as the human growth hormone protein.
Expression vector Expression vectors of the present invention contain, in addition to the above-mentioned DNA sequence coding for the BSF2 receptor linked with the DNA sequences necessary for the expression of the BSF2 receptor, an origin bf replication and at least one selective maker gene. These components of the expression vector are selected in accordance with the host organism used. For example, when a bacterium such as E.
coli is used as a host, an origin of replication is derived from conventional E. coli plasmids such as pBR322, pBR337 or the like. For a yeast host, the origin of replication is preferably Cal4 or a-Factor.
S% Where animal cells such as mammalian cells are used as host cells, the origin of replication is preferably derived from a virus such as the SV40 virus.
\o The choice of selective maker gene also depends 4 20 on the host organisms. Selective maker genes useful for bacterial hosts are, for example, ampicillin resistant gene, tetracycline resistant gene, or the like.
Host organism 25 In the present invention, any conventional host organisms including microorganisms, and animal cells can be used. As the bacterial hosts, various strains of E.
coli such as K-12, x-1776, w-3110, MC 1009 and the like are typically used. Moreover, Bacillus such as Bacillus S, 30 subtilis, Salmonella typhimurium, Serratia marcescens, Pseudomonas, and certain thermophilic bacteria can be used. As the yeast host, for example, Saccharomvces, such as Saccharomvces cerevisiae can be used, and as the mammalian host, cell lines such as COS cells derived from the renal fibroblast of a monkey, CHO cells (Chinese hamster ovary cells), WI38, BHK, 3T3, VERO, HeLa, etc., can be used.
17 Production of BSF2 receptor using transfo)mant The BSF2 receptor is producedl by culturing transformant cells prepared by transforming the abovementioned host with the above-mentioned expression vector to express the BSF2 receptor, and recovering the BSF2 receptor from the culture. The expression is induced by de-repression or activation of the promoter in the expression vector. Usually, the transformant cells are grown to a predetermined density under the condition wherein the promoter is repressed, after that the promoter is de-repressed or activated to express the BSF2 receptor. For this purpose, for example, indole acetic acid (IAA) for trp promoter, isopropyl-#-D-thiogalactopyranoside (IPTG) for tac promoter is used.
Antibodies to the BSF2 receptor .The present invention also provides antibodies to 0* the BSF2 receptor. The present antibodies include any antibodies specifically bound to the BSF2 receptor o, produced by any of the above-mentioned BSF2 receptor 2n producing cell lines, or to any of the above-mentioned $4 p recombinant BSF2 receptors. The antibodies may be polyclonal or monoclonal and may be produced by human, mouse, rabbit, sheep or goat, or by hybridoma derived 9 from there animals. As antigens used to immunize S 25 animals to produce polyclonal antibodies, or to prepare 0 hybridoma for the production of monoclonal antibodies, cells expressing the BSF2 receptor, BSF2 receptor proteins produced by the above-mentioned cell lines, and ga 40 various recombinant BSF2 receptor proteins can be used.
S 30 The present polyclonal and monoclonal antibodies S0″ can be produced according to a procedure known per se.
According to the present invention, the DNA sequence coding for the BSF2 receptor protein, expression vectors containing the DNA sequence, and the transformant containing the DNA sequence are provided.
By using the transformant, a large amount of the Boli2 receptor protein can be produced, which provides an .It -18opportunity to develop prophilactic and therapeutic pharmaceuticals as well as diagnostic agents relating to deseases or disorders associated with an abnormal production of the BSF2. Moreover, the availability of the BSF2 receptor protein in a purified form will accelerate the studies of an immune mechanism with which the BSF2 or BSF2 receptor is concerned.
Moreover, the DNA sequence per se. may be useful as a probe for screening related genes.
Examples The present invention will now be further illustrated by but is by no means limited to the following examples.
Example 1. Confirmation of presence of BSF2 receptor on some cell lines 000 *o o The BSF2 receptor specifically binds to BSF2 Taga et al., J. Exp. Med., 166, pp 967, 1987). By So””o using this property, the NK cell YT, monocyte U937 cell 0 00 0 0 line, myeloma U266 cell line, T-cell Jurkat cell line, r 0 a 20 B-cell CESS cell line, and B-cell BL29 cell line are tested for possession of the BSF2 receptor.
Cells of each of these cell lines were cultured in o o Dulbecco’s Modified Eagle’s Medium (D-MEM; Dulbeccos) 0 00 supplemented with 10% fetal calf serum (FCS) according to a conventional procedure. The BSF2 was prepared So according to a process described in Nature 324 pp 73 76, 1986. Note, the BSF2 can be also prepared o o, according to a process disclosed in Japanese Unexamined S* Patent Publication No. 61-24697.
3o N 1t w 30 Next, the BSF2 thus prepared was labeled with 125 according to a procedure described by T. Taga et al., J.
Exp. Med., 166, 967, 1987. The 125I-labeled BSF2 was reacted with the above-mentioned cultured cells according to a method of taga et al., supra. After the 125 I-labeled BSF2 non-specifically associated with the cells was washed away, the I which specifically binds to the BSF 2 producing cells was detected by a uuJ Q W AL IU *I IL %ll a
[I
19 scintillation counter. As a result, the presence of the BSF2 receptor was determined on cells of all of the cell lines tested, except for the B-cell BL29 cell line and T-cell Jurkat cell line.
Example 2. Isolation of mRNA I The isolation of mRNA was carried out according to Manistis et al., Molecular Cloning, Cold Spring Harbor Laboratory, 1982.
Monocyte U937 (ATCC-CRL-1593) was cultured by the same procedure as described in Example 1, and the cultured cells were washed with physiological saline. The washed cells were suspended in a solution of 50% guanidineisothiocyanate, and the solution was subjected to cesium chloride density-gradient centrioo°” 15 fugation using 5.7M cesium chloride and 2.7 cesium o chloride at 32000 rpm for 20 hours to obtain a mixture S0″ of m-RNA. The mRNA was suspended in a sodium lauroyl Go sarcosinate solution, and purified by phenol extraction .and ethanol precipitation.
t Example 3. Construction of cDNA library The mRNA fraction thus obtained was used as a temperate for a synthesis of cDNA, The synthesis was o” carried out using a cDNA synthesis kit (Applied o Biosystems) to obtain a cDNA library.
o Example 4. Cloning of desired cDNA clone S” As a host, COS cells (COS-7 oells) were used; and as a vector compatible to the COS cells, a CDM8 vector 0 0 described by Brian Seed, Nature 329, pp 840, 1987 was o used. The CDMS vector contains a cytomegalovirus S, 30 promoter and an origin of replication from the virus, as well as a restriction enzyme cleavage site /4 downstream of the cytomegalovirus promoter.
Excised cDNA’s were ligated to the CDM8 vector which had been digested with a restriction enzyme Bst X 1, and the resulting vectors containing a cDNA insert were used to transfect COS cells. Namely, COS cells were cultured in D-MEM supplemented with 10% FCS 1 00 a 0 0 0 00 0 0 0 04 9 a 4 04 0* 9 o 0 0 40 04 0 009 4 0 0 04 0 0 “o0 4 0 0 0 0 4 046 0 ?0 20 and transfection was carried out according to a DEAEdextran method, and the transfected COS cells were further cultured for two days. To the cultured COS cells was added a staining buffer (RPMI 1640 containing 2% FCS, 0.1% NaN 3 supplemented with biotinated BSF2, and the mixture was incubated at 37 0 C for two hours to allow binding of the BSF2 moiety of the biolinated BSF2 with the BSF2 receptor expressed on the cultured COS cells. The treated cells were then washed twice with the staining buffer (without the biotinated BSF2), and to 6ne washed cells was added avidin conjugated with fluorescein isocyanate (FITC) to allow binding of the avidin moiety of the avidin-FITC conjugate with the biotin moiety fixed to the cell. The treated cells were 15 then washed three times with the staining buffer.
After dead cells were eliminated by adding propidium iodide fluorescence-labeled COS cells were detected and isolated using a Fluorescein Activated Cell Sorter FACS; Becton Dickinson).
For comparison, the COS cells transfected with a vector not containing cDNA were treated according to the same procedure as described above.
Moreover the COS cells transfected with a cDNAcontaining vector were treated with the biotinated BSF2 in the presence of an excess amount of free BSF2 to allow competition between the biotinated BSF2 and the free BSF2 for binding to BSF2 receptor expressed on the COS cells. After the biotinated BSF2-treated COS cells were treated with the FITC-avidin according to the same 30 procedure as described above, the cells were analyzed by the FACS, and the results were as set forth in Fig. 1, wherein the abscissa axis represents the fluorescence intensity, and the ordinates axis represents the frequency of the number of cells carrying different fluorescence-intensities. In the Figure, A represents a result obtained from cells transfected with a vector not containing cDNA, B represents a result obtained from L 21 cells transfected with vectors containing a cDNA according to the present invention, and C represents a result obtained from cells transfected with vectors containing BSF2 receptor cDNA, but treated with the biotinated BSF2 in the presence of a excess amount of free BSF2.
The graph B shows the presence of cells having high fluorescence intensity, revealing that a population of cells transfected with vectors containing cDNA prepared according to the present invention contains a significant ratio of cells which produce a substance capable of binding to the BSF2. On the other hand, as seen from graph C, a population of cells treated with the biotinated BSF2 under a competitive condition with an o 15 excess amount of free BSF2 does not contain cells having 4″ 8 a high fluorescence intensity, revealing that the binding of the biotinated BSF2 with the COS cells is BSF2-specific.
From the cells having a high fluorescence S. 20 intensity, vectors were extracted and were used to transform E. coli MC1009 (ATCC 33760), and the trans- °o formants were cultured to amplify vectors containing a cDNA insert coding for the BSF2 receptor.
Q OOne vector thereamong was then chosen for further experiments and designated as pBSF2R.236.
The plasmid pBSF2R.236 partially digested with Xhol to obtain a DNA fragment containing a nucleotide sequence coding for an entire BSF2 receptor protein, and o o the DNA fragment was inserted to the Sal I site of S* 30 plasmid pIBI76 (commercially available from IBI) to consturct plasmid pIBIBSF2R. Escherichia coli containing the plasmid pIBIBSF2R was deposited with the Fermentation Research Institute Agency of Industrial Science and Technology, 1-3, Higashi 1-chome, Tsukuba-shi, Ibarakiken, Japan, under the Budapest treaty, on January 9, 1989, as FERM BP-2232.
The plasmid pIBISF2R can be cleaved with a suitable i 22 restriction enzyme(s) by a conventional procedure to obtain a DNA fragment containing a nucleotide sequence coding for a BSF2 receptor protein, and the DNA fragment can be used to construct further plasmids.
Example 5. Analysis of cDNA The vector DNA pBSF2R.236 prepared in Example 4 was digested with a retriction enzyme to excise the cDNA insert coding for the BSF2, and the determination of a restriction enzyme cleavage map and nucleotide sequence was carried out according to the M13 method of, J.
Messing, Methods in Enzymol. vol. 101, pp 20, 1983.
The results are set forth in Figs. 2 and 3-1 to The DNA coding for the BSF2 receptor consists of 1404 base pairs flanked by a translation start codon ATG °oo, 15 at the 5′-terminal and a translation stop codon TAG at oO, s the 3′-terminal.
o Example 6. Confirmation of cDNA coding for BSF2 o0 0 receptor To confirm that the cloned cDNA codes for the 20 target BSF2 receptor protein, the above-mentioned cell lines, NK cell line YT, monocyte cell line U937, o, myeloma cell line U266, T-cell Jurkat, B-cell CESS, and a” e B-cell BL29, were cultured and mRNA was extracted from 1 08 o o each culture and purified according to the same procedure as described in Example 2.
The purified mRNA was concentrated by oligo-dT resin (Boehringer), and 1 pg of the concentrated mRNA o was subjected to 0.8% agarose gel electrophoresis and transferred to a nitrocellulose filter by Northern S° 30 blotting.
On the other hand, the vector DNA prepared in Example 4 was digested with a restriction enzyme Xhol to excise the DNA fragment coding for the BSF2 receptor, which was then nick-translated to prepare a probe.
For hybridization, the above-mentioned Northernblotted nitrocellulose sheet was placed in contact with a hybridization buffer comprising 50% formaldehyde, 5 x
I
i
‘I
$1 ii 0 00 0t 0* 0 006 S* 0 23 Denhart (1 x Denhart 0.02 g/100 ml Ficoll polyvinyl pyrrolidone and 0.02 g/ml bovine serum albumin), 5 x SSC (1 x SSC 8.77 g/l NaCI and 4.41 g/l sodium citrate, pH and 10 Ag/ml salmon sperm DNA supplemented with 5 1 x 107 cpm/ml of the above-mentioned probe, at 42°C for 24 hours.
After the hybridization, the nitrocellulose sheet was washed twice in 1/10 SSC at 50°C for 20 minutes each to eliminate the probe non-specifically associated with the nitrocellulose sheet, and then dried. The sheet was exposed to an X-ray film for autoradiography, and the results were as set forth in Fig. 4.
As seen from the Figure, mRNA’s extracted from monocyte cell line U937, myeloma cell line U266, B-cell line CESS, and NK cell line YT, which were previously confirmed as expressing the BSF2 receptor in Example 1, hybridized with the cloned cDNA. On the other hand, mRNA’s extracted from the B-cell line BL29 and T-cell line Jurkat, which were previously confirmed as not 20 expressing the BSF2 receptor, did not hybridize with the icloned DNA. This result supports the fact that the cloned cDNA of the present invention actually codes for the BSF-2 receptor protein.
Note, T. Taga, supra, disclosed the number of BSF2 receptor per cell for some cell lines, as follows: Cell line Number of cells on cell membrane U937 3 x 10 3 /cell U266 2 x 10 4 /cell CESS 3 x 10 3 /cell BL29 negative Jurkat negative YT 5 x 10 3 /cell 0 0 0* a 0 0 00 0 0 00 24 The T. Taga et al. result also supports the abovementioned conclusion.
Figure 3 represents, in addition to the DNA sequence of the present invention, a presumed amino acid sequence of the present BSF2 receptor consisting of 468 amino acid residues whose N-terminal amino acid is methionine corresponding to the translation start codon.
The amino acid sequence contained two hydrophobic regions, one of which was positioned at the N-terminal side and was considered to be a signal peptide, and another of which was positioned on the C-terminal side and was considered to be a region responsible for the penetration of the protein through the cell membrane.
This supports the assumption that the BSF-2 receptor o 15 penetrates the cell membrane and reaches the inside of the cell.
SExample 6. Construction of plasmid PABSF2RI.1 0%00 (Fict. 51 o D) To prepare a plasmid containing a DNA coding for a D 20 modified BSF2 receptor protein wherein a central portion of the native protein is deleted, the plasmid pBSF2R.236 o 0 prepared in Example 4 and containing a cDNA coding for an entire BSF2 receptor protein was used.
The plasmid pBSF2R.236 was cleaved with Hind III and Mrol, and a generated DNA fragment was blunt-ended with a Klenow fragment of DNA polymerase, and cleaved with XhoI to obtain a DNA fragment A. Further, 4° 0oo pBSF2R.236 was cleaved with SspI and PstI to obtain an o o 800 bp DNA fragment B. Still further, a CDM8 vector was 0 30 cleaved with XhoI and PstI, and treated with BAP to obtain a vector fragment C. The above-mentioned fragments A, B and C were then ligated using a ligase, and the ligati mixtures were used to transform R. coli MC1061/P3, and a colony resistant to 125 Ag/ml ampicillin and 75 pg/ml tetracycline was selected as a desired clone, from which a plasmid was obtained, and designated p3SF2RI..
This plasmid contains a DNA coding for a protein consisting of amino acids 1 to 123 and 343 to 468 ir, the amino acid sequence and lacking a DNA portion coding for amino acids 124 to 342.
Example 7. Construction of plasmid (Fiq. 6) To prepare a plasmid containing a DNA coding for a modified BSF2 vector protein, wherein a portion near the N-terminal of the native BSF2 receptor protein was deleted, the plasmid pBSF2R.236, prepared in Example 4, containing a cDNA coding for an entire BSF2 receptor protein, was used.
The plasmid pBSF2R.236 was cleaved with XhoI and FspI to isolate a 450 bp DNA fragment D. Further, So.o 15 pBSF2R.236 was cleaved with ApaLI and XbaI to isolate a Oo 1.5 kbp DNA fragment, which was then treated with Muag bean nuclease, and cleaved with PstI to obtain d DNA 4 000 fragment E. Moreover, a CDM8 vector was cleaved with o Xhol and PstI, and treated with BAP to obtain a vector 0″ 20 DNA fragment F. Next, the above-prepared DNA fragments D, E, and F were ligated using DNA ligase. The ligation Oo.u mixture was used to transform coli MC1061/P3, and a colony resistant to 125 pg/ml ampicillin and 75 pg/ml S” tetraagcline was selected to obtain a desired clone, 25 from which a plasmid was obtained and designated This plasmid contained a DNA coding for protein consisting of amino acids 1 to 27 and 110 to 468 of the o amino acid sequence and lacking a DNA portion S” 30 coding for amino acids 28 to 109.
Example 8. Confirmation of expressions of BSF2 receptor protein Plasmid pBSF2R.236 constructed in Example 4, plasmid pABSF2RI.1 constructed in Example 6, and plasmid pABSF2RII.5 constructed in Example 7 were separately transfected to mouse COP cells Tyndall et al., Nucleic Acid Res., 9, 6231, 1981) by the DEAE-dextran h A 26 method (Secd, B. and Aruffo, PNAS, 84: 3365), and the cells were cultured in a DMEM medium containing fetal calf serum (FCS). Using the same procedure as described in Example 1, it was determined whether the cultured cells expressed a desired protein, in a cell sorter using fluorescence staining (FACS440). The results are shown in Fig. 7 (for pBSF2R.236), Fig. 8 (for pABSF2RI.1), and Fig. 9 (for pABSF2RII.5). As seen from these Figures, although COP cells transfected with pBSF2R.236 (Fig. 7B) and COP cells transfected with (Fig. 9B) were stained, COP cells transfected with paBSF2RI.1 (Fig. 8B) were not stained. The staining was prevented by the addition of an excess amount of recombinant BSI2 (Fig. 7C and Fig. 9C). As a o° o 15 result, it was confirmed that both the pBSF2R.236 and pBSF2RII.5 provide a protein having a BSF2 receptor activity, revealing that a protein wherein a protein of 6 004 ac the amino acid sequence near the N-terminal of the native BSF2 receptor protein has been deleted, exhibits 4* 20 a BSF2 receptor activity.
Example 9. Production of soluble BSF2 receptor protein (Figs. 10 and 11) To produce a soluble BSF2 receptor protein, a protein wherein a portion expected to be a membrane 25 penetration region and a portion expected to be an intracellular protein region present at a C-terminal of the BSF2 receptor protein were deleted, was prepared.
To this end, an expression plasmid ph 8 ABSF2R was con- 4 3 structed which comprised a vector portion based on 30 plasmid PUC9; a BSF2 receptor expression unit comprising a human P actin promoter Nakajima et al., Proc.
Natl. Acad. Sci. USA, 82, 6133, 1985), a soluble BSF2 receptor cDNA, and a translation stop codon linked in this order, Namely, the plasmid pBSF2R.236 was cleaved with Sphl to obtain a cDNA fragment containing codons for a first amino acid to a 402th amino acid of the native
I
27 BSF2 receptor. This fragment was inserted to a phage vector M13 mpl8 at the SphI site thereof, and site specific in-vitro mutagenesis was carried out using an oligonucleotide primer 5′-ATATTCTCTAGAGAGATTCT-3′ and a site specific in-vitro mutagenesis system (Amersham) to prepare a mutant phage M13 mpl8 (345) wherein a TAG termination codon had been inserted immediately after the 344th amino acid codon. This mutant phage in a replicating form was cleaved with Hind III and SalI to obtain a DNA fragment coding for an N-terminal side of the BSF2 receptor protein wherein a 345th amino acid codon had been replaced by a translation termination codon TAG. Moreover, a plasmid pECE Ellis et al., co. Cell, 45, 721, 1986) containing f-globin poly A was 15 cleaved with SalI and BamHI to obtain a DNA fragment (B) S containing P-globin poly A. Further, a plasmid Soo comprising a human P actin promoter inserted in a 0o plasmid PUC9 was cleaved with HindIII and BamHI to 0 S obtain a linear plasmid comprising a human P actin promoter and PUC9 vector. Next, these DNA fragments were ligated using DNA ligase to construct an expression Q0*4 S plasmid phPABSF2R. A process for the construction of this plasmid and the structure thereof are shown in Fig. 25 Soluble BSF2 receptor protein was prepared using the plasmid phPABSF2R, as follows. To mouse fibroblast cells (L cells, ATCC CCL1) cultured in a DMEM medium by S” a conventional procedure was added 20 pg/petri dish of ph#ABSF2R using a calcium phosphate method kit (Pharmacia). The medium was replaced the next day, and after a further culturing for two days, a culture supernatant was recovered. Detection of the soluble BSFZ receptor protein in the supernatant was carried out using an MT18 antibody prepared by the procedure described in Example 11 and 125 I-BSF2 prepared by the procedure described in Example 1. Namely, 100 il each of PBS containing 1 Ag/ml of an MT18 antibody was put
I
28 into each well of a 96-well microtiter plate, and the plate was incubated at 4 0 C overnight. After washing, 100 Al/well of 1% BSA was added, and the plate was incubated for two hours at room temperature.
After washing, 100 pl/well of the above-mentioned culture supernatant from the L medium was added, and the plate was incubated at a room temperature for two hours, and then washed. Next, 100 Al/well 125 of 125I-BSF2, corresponding to 20,000 cpm/well, was added to the well, and the plate was incubated at room temperature for two hours, and then washed. The plate was cut to separate each well, and bound radioactivity was measured by a 7-counter. Further, to confirm the 0, q specificity of the product, the above-mentioned o o 15 procedure was carried out using the supernatant o* o supplemented with 200 ng/ml of non-labeled BSF2 0 °o0 instead of the supernatant alone.
For comparison, DMEM containing 10% FCS but not o, g inoculated with cells, and a culture supernatant of L 0 20 cells not transfected with plasmid were treated by the same procedure described above, and bound radioactivity was measured by a 7-counter.
The results are shown in Fig. 11. As seen from this Figure, in contrast with the DMEM medium containing *oo” o 25 10% FCS and a culture supernatant of L cells not transfected with plasmid, a culture supernatant of L cells transfected with ph#ABSF2R contained a substance r°a which binds to both the TM18 antibody and 125 1-BSF2.
Further, where a culture supernatant of L cells transfected with phPABSF2R and supplemented with 200 ng/ml non-labeled BSF2 was added instead of the supernatant alone, the bound radioactivity was significantly reduced. This shows that the product is a soluble BSF2 receptor.
Example 10 Production of soluble BSF2 receptor protein (Figs. 12 to 18) Construction of plasmid pSVL345 e 0 0 0 0 0 00 0 00 4 a 0 90 o00 00 0 a 00 4 4 0 t ar 29 To produce a soluble BSF2 receptor protein in COS-1 cells, protein wherein a portion expected to be a membrane penetration region and a portion expected to be an intracellular protein region present at a C-terminal of the BSF2 receptor protein were deleted, was prepared.
To this end, an expression plasmid pSVL345 was constructed which comprised a vector portion based on plasmid pSVL (Pharmacia); a BSF2 receptor expression unit comprising an SV40 late promoter contained in pSVL, a soluble BSF2 receptor cDNA, and a translation stop codon linked in this order; and SV40 polyadenylation signal.
Namely, the plasmid pBSF2R.236 was cleaved with Sphl to obtain a cDNA fragment containing codons for a first amino acid to a 402th amino acid of the native BSF2 receptor. This fragment was inserted to a phage vector M13 mpl8 at the SphI site thereof, and site specific in-vitro mutagenesis was carried out using an oligonucleotide primer 5′-ATATTCTCTAGAGAGATTCT-3′ and a site specific in-vitro mutagenesis system (Ameram) to prepare a mutant phage M13 mpl8 (345) wherein a TAG termination codon had been inserted in place of the 345th amino acid codon. This mutant phage in a replicating form was cleaved with Hind III and SalI to obtain a DNA fragment coding for an N-terminal side of the BSF2 receptor protein wherein a 345th amino acid codon had been replaced by a translation termination codon TAG.
This DNA fragment was inserted in the SphI site of a plasmid pSP73 (available from Promegabiotch) to construct a plasmid wherein the DNA fragment has been inserted so that the XhoI site is present near to the of BSF2 receptor and the BamHI site is present near to the 3’-side of the BSF2 receptor gene. This plasmid was cleaved with Xhot and BamHI to obtain a DNA fragment containing a nucleotide sequence coding for 344 amino acids )f the N-terminal side of a BSF2 30 receptor. On the other hand, the basic plasmid pSVL was cleaved with XhoI and BamHI, and treated with alkaline phosphatase to obtain a linearized plasmid DNA. Next, this linearized DNA and the DNA fragment were ligated with T4 DNA ligase to construct an expression plasmid pSVL345. A process for the construction of this plasmid is set forth in Fig. 12.
Construction of plasmid pSVL324 To produce a soluble BSF2 receptor protein, a protein wherein a portion expected to be a membrane penetration region and a portion expected to be an intracellular protein region present at a C-terminal of the BSF2 receptor protein were deleted, was prepared.
on., To this end, an expression plasmid pSVL345 was 15 constructed which comprised a vector portion based on 4 0 0 o; plasmid pSVL (pharmacia); a BSF2 receptor expression Soo unit comprising an SV40 late promoter contained in pSVL; 4* a soluble BSF2 receptor cDNA, and a translation stop 4. S codon linked in this order; and SV40 polyadenylation S 20 signal.
Namely, the plasmid pBSF2R.236 was cleaved with 4000 ‘Qo 0 Sphl to obtain a cDNA fragment containing codons for a o first amino acid to a 402th amino acid of the native BSF2 receptor. This fragment was inserted to a phage ,0o* 25 vector M13 mpl8 at the SphI site thereof, and site specific in-vitro mutagenesis was carried out using an oligonucleotide primer 5,-GTCCTCCAGTCTAGAACGAGGT-3′ and 00 So” a site specific in-vitro mutagenesis system (Amersham) to prepare a mutant phage M13 mpl8 (324) wherein a TAG termination codon had been inserted in place of the 324 amino acid codon. This mutant phage in a replicating form was cleaved with SphI to obtain a DNA fragment coding for an N-terminal side of the BSF2 receptor protein wherein a codon for 323th alanine has been changed to a codon for valine and a 324th amino acid codon had been replaced by a translation termination codon TAG.
iV
I?
31- This DNA fragment was inserted in the SphI site of a plasmid pSP73 (available from Promegabiotch) to construct a plasmid wherein the DNA fragment has been inserted so that the XhoI site is present near to the 5′-side of BSF2 receptor and the BamHI site is present near to the 3’-side of BSF2 receptor gene. This plasmid was cleaved with XhoI and BamHI to obtain a DNA fragment containing a nucleotide sequence coding for 323 amino acids of the N-terminal side of a BSF2 receptor. On the other hand, the basic plasmid pSVL was cleaved with XhoI and BamHI, and treated with alkaline phosphatase to obtain a linearized plasmid DNA. Next, this linearized DNA nd the DNA fragment were ligated with T4 DNA ligase to construct an expression plasmid 15 pSVL324. A process for the construction of this plasmid is set forth in Fig. 13.
So Expression of soluble BSF2 receptor protein An expression of a soluble BSF2 receptor protein using the above-mentioned plasmids pSVL345 and pSVL324 was carried out as follow. COS-1 cells (ATCC CRL 1650) derived from kidney cells of an African green monkey *o were cultured in DMEM supplemented with 10%(v/v) fetal 4 c°o calf serum (Gibco), by a conventional procedure. To the cultured cells, the plasmids pSVL345 and pSVL324, and 25 plasmid pSVL (Moch) not containing the BSF2 expression unit, were separately transfected by a calcium phosphate method (Wigler et al. Cell, 14, 725 731, 1978).
r 0 6 S° Namely, for each palsmid, x10 cells/10 ml was put into Aoi a petri disk having a diameter of 100 mm, and cultured overnight, and 20 g of plasmid in 1 ml of calcium phosphate solution (Chu, G. and Sharp, Gene, 13, 197 202, 1981) was added to each culture, the next day, the medium was exchanged and 10 ml of the medium was added, and after a further culturing for three days, a supernatant was recovered.
Detection of soluble BSF2 receptor in supernatant First, an enzyme immunoassay was carried out using 32 an MT18 antibody described in Example 11. Namely, the supernatant prepared as described above was diluted, and 200 1l of the diluted supernatant was put into each well of 96-well microtiter plate. After incubation at 4°C overnight, the plate was washed with a washing solution.
Next, 1% of a BSA solution was added to each well, and the plate was allowed to stand at a room temperature for minutes, to block the wells. Next, the plate was washed, and the MT18 antibody was added to the wells and incubation was carried out at a room temperature for minutes. Again the plate was washed, and an antimouse IgG26 rabbit antibody was added to the wells, and incubation was carried out at a room temperature for ,oo 60 minutes, then after washing the plate, an enzyme- 15 labeled anti-rabbit IgG goat antibody was added to S^ the wells, an incubation was carried out at a room So temperature for 60 minutes. After again washing the plate, p-nitrophenyl phosphate as a substrate was added SI4 to the wells to carry out an enzyme reaction for minutes, and after the reaction, the absorbance (O.D.
405 600 nm) was measured by a microplate reader 0 0 ,o (Toso, Japan).
0 o The result is set forth in Fig. 14, As seen from the Fig. 14, supernatants from COS-1 cells “”pi 25 transfected with pSVL345 and pSVL324, respectively, contained a product which binds to the MT18 antibody, but a supernatant from COS-1 cells transfected with S* pSVL not containing the BSF2 receptor expression unit 44 i* did not contain a product which binds to the MT18 antibody.
Next, a soluble BSF2 receptor in the supernatants was detected by a method using the MT18 antibody and 125 I-BSF2, by the same procedure as in Example 9. The result is set forth in Fig. 15. As seen from the Fig. 15, in comparison to the supernatant from COS-1 cells transfected with pSVL, the supernatants from COS-1 cells transfected with pSVL345 and pSVL324,
A..
tI 33 respectively, contained a product which binds to both the MT18 antibody and 25 I-BSF2. Moreover, where cold BSF2 was added to the supernatant, the count was dose-dependently decreased. This confirms that the product in the supernatant was a soluble BSF2 receptor (see Fig. 16).
As another confirmation, the presence of a soluble BSF2 receptor in the supernatant was confirmed by a method using the MT18 antibody, BSF2, and an anti-BSF2 rabbit antibody. Namely, 200 1p of 5 pg/ml MT18 antibody was added to each well of a microtiter plate, and the plate was incubated at 40 0 C overnight. After washing the plate, the wells were blocked with 1% of a o BSA solution at a room temperature for 90 minutes, and 15 after again washing the plate, a suitably diluted culture supernatant was added to the well, and an gii incubation was carried out at a room temperature for 4 4 0 60 minutes. Then, after washing, a 100 ng/ml BSF2 solution containing 10% FCS was added to the well, which was incubated at a room temperature for 60 minutes.
Again after washing, 500 ng/ml anti .BSF2 rabbit IgG ‘o 0 o antibody was added to the well, and incubation was 0 carried out at a room temperature for 60 minutes, and o oQ after another washing, an enzyme-labeled anti-rabbit IgG 0 25 goat IgG antibody was added to the well and incubation was carried out at a room temperature for 60 minutes.
Subsequently, the plate was treated by the same procedure as described above. The result is set forth E in Fig. 17. In comparison with a supernatant from COS-1 cells transfected with pSVL, it was confirmed that supernatants from COS-1 cells transfected with pSVL345 and PSVL324, respectively, contained a product which binds to both the MT18 antibody and BSF2.
Finally, the supernatants were subjected to SDSpolyacrylamide gel electrophoresis, the electrophoresis pattern was transblotted to a nitrocellulose sheet, and the MT18 antibody was added to the microcellulose sheet.
%L
34 i Next, to the nitrocellulose sheet was added a biotinated anti-mouse IgG antibody followed by streptoividinalkaline phosphatase. Finally, NBT/BCIP as a substrate was added to the nitrocellulose sheet to develop the products. The result is set forth in Fig. 18. Supernatant from COS-1 cells transfected with pSVL324 exhi- Ij bited a band at 42kD, and supernatant from COS-1 cells transfected with pSVL345 exhibited a band at revealing the presence of a soluble BSF2 receptor in the supernatants.
Figure 19 represents the structures of proteins produced in Examples 8, 9, and 10. In this figure, BSF2R.236 is a protein produced by a plasmid pBSF2R.236, m. and corresponds to native BSF2 receptor. ABSF2RI.1 S 15 represents a protein produced by a plasmid pBSF2RI.1, 5 BSF2RII.5 represents a protein produced by a plasmid So.. pABSF2RII.5, SVL324 represents a protein produced by a i plasmid pSVL324, hIABSF2R represents a protein produced 4S 6by a plasmid phPABSF2R and SVL345 represents a protein produced by plasmid pSVL345. Since not only BSF2R.236, but also ABSF2RII.5, DRN1, and hPABSF2R exhibit a BSFR I:.o receptor activity, it was con’firmed that shortened proteins wherein a portion of the amino acid sequence near the N-terminal of the native BSF2 receptor protein 25 has been deleted, and shortened proteins wherein a portion of C-terminal including a membrane penetration region and an intracellular protein region of the native BSF2 receptor protein has been deleted, still exhibit a 0 BSF2 receptor activity.
Example 11. Production of monoclonal antibody to BSF2 receptor To prepare an immunogen for the production of a monoclonal antibody to the BSF2 receptor, a mouse T cell line expressing human BSF2 receptor on the surface was prepared as follows. The plasmid pBSF2R.236 described in Example 4 and the plasmid pSV2 neo were cotransfected to cells of a mouse cell line CTLL-2 (ATCC TIB214), then
L
35 subjected to a screening procedure using G-418, and eventually a cell line expressing about 30,000/cell of BSF2 receptor was established, and designated as CTBC3.
The CTBC3 cells were cultured in RPMI 1640 by a conventional procedure, and the cultured cells were washed three times with PBS buffer. The washed cells were intraperitonealy injected to C57BL6 mouse in an amount of 1 x 107 cells/mouse, once a week for a total of six times, to immunize the mouse, Spleen cells from the immunized mouse were fused with a myeloma cell line P301 by a conventional procedure using polyothyleneglycol, and a desired hybridoma was selected as follows. A human T cell line JURKAT (ATCC CRL8163), which is BSF2 receptor negative, was cotransfected with oo 15 pBSF2R.236 and pSV2 neo, and the transfected cells were S’ screened. A cell line, which expresses 100,000/cell of S« BSF2 receptor, was established and designated as NJBC8.
One clone of hybridoma, which recognizes NJBC8 cells Sdo lyzed with NP40 and does not recognize JURKAT cells S 20 lyzed with NP40, was isolated and designated as MT18.
An monoclonal antibody produced by the hybridoma MT18 is designated as an MT18 antibody. Figure 20 shows that oa the MT18 antibody specifically recognizes the BSF2 receptor. In this figure, A represents a graph of fluorescence intensity versus cell frequency where JURKAT cells were stained by an MT18 antibody labeled with fluoresceinisocyanate, and B represents a similar 1 .O result where NJBCB cells were similarly stained.
8% 0 The claims form part of the disclosure of this specification.
4a “O

Claims (23)

1. An Isolated receptor protein for human B cell stimulating factor-2, capable of specifically binding to the human B cell stimulating factor-2. A wncorviU-d’

2. An g ioat protein according to claim 1, wherein the receptor protein is selected from the group consisting of a protein having the following amino acid sequence (N-terminal) 0 0 4* 44 44* V U Met Leu Arg Val1 Leu Ala Ala Gly His Gly Asp Phe Glu Thr As n Gin Gin Tyr Gly Gly Asn Arg Ser Glu Phe His Arg Phe Leu Ala Val Leu Ala Ala Arg Cys Pro Leu Thr Ser Thr Cys Pro Thr Val His Gly Ger His Arg Arg Leu Asp Ser Gly Arg Pro Ala Val Pro Pro Arg Lys Ser Trp Gly Pro Lys Ala Val Ser Pro Ala Tyr Ser Gin Leu Ala Val Ile Val Ser Ser Lys Phe Cys Gly Ilie Ile Thr Val Trp Leu Ser Trp Asn Ser lieu Arg Tyr Thr Thr Trp Cys Val Ile Hi4s Val Val Gly Gln Gly Gly Pro Ala Leu Gly Trp Pro Leu Asn G ly Glu Pro Arg Leu G lu Giu Pro Met Ser Leu Thr Val1 Ser Arg Met His Gin Glu Cys Ala Leu Gly Ala Ala Gln Glu Val Pro Gly Asp Val Glu Pro Val Leu Arg Ser Arg Trp Leu Arg Ser Tyr Ser Cys Thr Val His Glu Pro Gin Leu Ser Asn Ser Thr Pro Leu Val Arg Asp Phe Gin Ser Gin Lys Giu Gly Asp Cys Val Ala Lys Thr Gin Gin Pro Asp Ala Val Ala Leu Leu Ala Ser Glu Lys Ala Val Tyr Leu Leu Val Ser Lys Giu Phe Ser Ser Thr Pro Arg Ala Ala Arg Val1 Asp Pro Gly Gin Arg Leu Ser Val Leu Phe Pro Ser Ser Ser Phe Pro Asn Ala Pro Gly Thr As ri Ala Met Leu Ala Val Cys Cys Thr Gin Cys Cys Phe Val Gin Ala Pro Wf~ *4 4* 4 4 4 *4 4 4 4 Thr Trp Gin Asp Pro Phe Tyr Arg Leu Arg Ala Giu Arg Ser Lys Val Lys Asp Leu Gin Asp Ala Trp Ser Gly Leu Arg Ala Gin Glu Trp 5cr Giu Trp Ser His Phe Thr His Leu Giu Pro ~F CT~-ijlli~ El 37 Glu Ala Met Ser Pro Pro Met Gln Ala Asn Ile Leu Ser Leu Pro Leu Pro Thr Ala Phe Gly Leu Arg Phe Leu Lys Glu Tyr Ser Leu Arg Pro Thr Pro Pro Val Asn Thr Ser Asp Pro Arg Asp Tyr Phe Gly Thr Pro Ala Glu Asn Leu Thr Thr Phe Arg Asp Val Gin Asp Phe Leu Val Thr Leu Leu Lys Lys Thr Gly Lys Thr Gly Gin Leu Pro Val Leu Ser Pro Ser Ser His Asn Ser Pro Tyr Phe Pro Arg (C-termr Trp Thr Glu Glu Val Ser Asn Lys Asp Ser Ala Asn Ser Ser Ser Ala Gly Gly Cys Ile Ala Trp Lys Leu Ser Met His Val Pro Glu Val Pro Leu Ser Leu Cly Arg Pro Asp Asp Ile Ser nal inal) Ser Arg Thr Pro Asp Asp Ala Thr Val Pro Ser Leu Ile Val Arg Ala Pro Pro Arg Pro lie Ser Ser Asp Ala Arg Asn Thr a 4 44a 2 10 44 14 4 4 ai a a protein wherein one or more than one amino acid residue has been deleted from the amino acid sequence maintaining the biological activity of the native protein, a protein wherein one or more than one amino acid residue has been added to the amino acid sequence maintaining the biological activity of the native protein, and a protein wherein one or more than one amino acid residue has been replaced by one or more than 25 one other amino acid residue, maintaining the biological activity of the n tive protein.

3. -An- ioslatcd protein according to claim 2, wherein the protein has the amino acid sequence from which amino acid residues near the N-terminal are deleted.

4. -Ad–i-eeped-protein according to claim 3, wherein said-protein has the following amino acid sequence (II): (N-terminal) Met Leu Ala Val Gly Cys Ala Leu Leu Ala Ala Leu Leu Ala Ala Pro Gly Ala Ala Leu Ala Pro Arg Arg Cys Pro Ala Val Asp Val Pro Pro Glu MW 38 0 0 0 0 0 0 0 00 0 00 000 0 00 040 0 00 o00a 000000 0 0 Giu Pro Gin Leu Ser Leu Ser Asn Val Val Ser Thr Pro Ser Leu Leu Val Arg Lys Phe Asp Phe Gin Glu Pro Ser Gin Lys Phe Ser Giu Gly Asp Ser Ser Cys Val Ala Ser Ser Lys Thr Gin Thr Phe Gin Pro Asp Pro Pro Ala Vai Ala Arg Asn Thr Trp Gin Asp Pro Phe Tyr Arg Leu Arg Ala Giu Arg Ser Lys Val Lys Asp Leu Gin Asp Ala Trp Ser Gly Leu Arg ‘,la Gin Giu Trp Ser Glu Trp Ser Pro Trp Thr Glu Ser Asn Glu Val Ser Thr Thr Asn Lys Asp Asp Asp Sor Ala Asn Ala Asp Ser Ser Ser Val Val Ala Gly Gly Ser Leu Cys Ile Ala Ile Thr 9Trp Lys Lau Arg Thr Ser Met His Pro Leu Val Pro Glu Arg Leu Val Pro Leu Ile Ser Ser Leu Glty Ser Asn Arg Pro Asp Ala Tyr Asp Ile Ser Asn Arg. e=beprti Cys Phe Arg Lye Ser Pro Cys Glu Trp Gly Pro Arg Thr Thr Lye Ala Val Leu Gin Asn Ser Pro Ala Glu Cys Gin Tyr Ser Gin Giu Cys Gin Leu Ala Vai Pro Phe Tyr Ile Val Ser Met Val Giy Ser Lye Phe Ser Gin Gly Cys Gly Ile Leu Ala Aen Ile Thr Val Thr Pro Arg Trp Leu Ser Val His Ser Trp Aen 5cr Ser Phe Giu Leu Arg Tyr Arg Thr Phe Thr Thr Trp Met His His Cys Val Ile His Leu Arg His Val Val Gin Giu Phe Gly Gin Gly Glu Pro Giu Ala Met Gly Thr Zkrg Ser Pro Pro Ala Glu P’ro Met Gin Ala Leu Thr Asp Aen Ile Leu Phe Arg Thr Ser Leu Pro Val Gin Pro Leu Pro Thr Phe Leu Lau Ala Phe Gly Thr Leu Val Leu Arg Phe Lye Lye Ala Lau Lye Glu Gly Lye Pro Tyr Ser Leu Gly Gin Pro Arg Pro Thr Pz-o Val Ser Pro Pro Vali 5cr Pro Asp Asn Thr Ser Ser His Arg Asp Pro Arg Ser Pro Thr Asp Tyr Phe Phe Pro according to claim 2, wherein the protein has the amino acid sequence from which amino acid residues i~t the C-terminal are deleted. f k x 39 A1 “Z-COM410a~A

6. A~n ir-Qi-ted protein according to claim wherein the protein has the following sequence (III): (N-terminal) amino acid Met Leu Ala 0404 o 0 0 00 0 0 0 00 60 4 4 4* 4004 44 40 4 O 44 0 0 0 40 444444 4 4 44 46 B 4 0 00 4 o ~0 0 40 Leu Leu Arg Arg Val Leu Leu Thr Ala Thr Ala Giy Gly Arg His Asp Gly Arg Asp Val Phe Arg Glu Trp Thr Lys Asn Ser Gin Tyr Gln Leu Tyr Ile Gly Ser Gly Cys Asn Ile Arg Trp Ser Trp Glu Leu Phe Thr His Cys Arg His Phe Gly Glu Ala Ser Pro Ala Cys Thr Cys Val1 Ser Arg Ser Pro Pro Lys Gly Ala Pro Ser Ala Val1 Lys Gly Thr Leu Asn Arg Thr Val£ Val1 Gin Met Pro Val Gly Cys Ala Ala Pro Gly Ala Pro Ala Gin Glu Ser Leu Pro Giy Pro Gly Val Glu His Trp Val Leu His Pro Ser Arg Leu Leu Leu Arg Gly Asn Tyr Ser Ala Gly Thr Val Pro Glu Glu Pro Ser Pro Leu Ser Pro Arg Ser Thr Val Leu Leu Val Ala Giu Asp Phe Gin Glu Ser Gin Val Pro Glu Gly Ser Met Cys Val Phe Ser Lys Thr Ile Leu Gin Pro Val Thr Ala Val Ser Val Thr Trp Ser Ser Phe Tyr Tyr Arg Ala Glu Trp Met Val Lys Ile His Asp Ala Val Gin Leu Arg Gly Glu Trp Ser Gly Thr Pro Trp Val. Leu Ala Val1 Asp Pro Arg Trp Ser Cys His Gin As n Pro Arg Gin Lys Asp Ala Gin Asp Ala Gin Arg Arg Asp Trp Ala Glu Thr Leu Ala Ala Leu Ala Pro Ala Arg Gly Ser Val Thr Glu Asp Asn Lys Pro Ala Ala Giy Met Val Gin Leu Tyr Arg Aia Leu Leu Val Leu Ser Cys Val Val Cys Ser Leu Thr Lys Phe Gin Glu Pro Cys Phe Ser Cys Ser Ser Phe Ser Ser Val Thr Phe Gin Pro Pro Ala Arg Asn Pro Asp Pro His Leu Arg Phe Ser Lys Thr Leu Gin His Ser Giy Leu Gin Glu Glu Trp Ser Pro Glu Ser Arg

7. “An i rolat protein according to claim wherein the protein has the following amino acid A. 40 sequence 04 0 0 0 090 0 0 000 0 00 00 0 a 0 0 (IV): (N-terminal) Met Leu Ala Val Gly Cys Ala Leu Leu Ala Ala Leu Leu Ala Ala Pro Gly Ala Ala Leu Ala Pro Arg Arg Cys Pro Ala Gln Glu Val Ala Arg Gly Val Leu Thr Ser Leu Pro Gly Asp Ser Val Thr Leu Thr Cys Pro Gly Val Glu Pro Glu Asp Asn Ala Thr Val His Trp Val Leu Arg Lys Pro Ala Ala Gly Ser His Pro Ser Arg Trp Ala Gly Met Gly Arg Arg Leu Leu Leu Arg Ser Val Gln Leu His Asp Ser Gly Asn Tyr Ser Cys Tyr Arg Ala Gly Arg Pro Ala Gly Thr Val His Leu Leu Val Asp Val Pro Pro Glu Glu Pro Gln Leu Ser Cys Phe Arg Lys Ser Pro Leu Ser Asn Val Val Cys Glu Trp Gly Pro Arg Ser Thr Pro Ser Leu Thr Thr Lys Ala Val. Leu Leu Val Arg Lys Phe Gln Asn Ser Pro Ala Glu Asp Phe Gln Glu Pro Cys Gln Tyr Ser Gln Glu Ser Gln Lys Phe Ser Cys Gln~ Leu Ala Val Pro Glu Gly Asp Ser Ser Phe Tyr Ile Val Ser Met Cys Val Ala Ser Ser Val Gly Ser Lys Phe Ser Lys Thr Gln Thr Phe Gln Gly Cys Gly Ile Leu Gln Pro Asp Pro Pro Ala Asn Ile Thr Val Thr Ala Val Ala Arg Asn Pro Arg Trp Leu Ser Val Thr Trp Gln Asp Pro His Ser Trp Asn Ser Ser Phe Tyr Arg Leu Arg Phe Glu Leu Arg Tyr Arg Ala Glu Arg Ser Lys Thr Phe Thr Thr Trp Met Val Lys Asp Leu Gln His His Cys Val Ile His Asp Ala Trp Ser Gly Leu Arg His Val. Val. Gln Leu Arg Ala Gln Glu Glu Phe Gly Gln Gly Glu Trp Ser Glu Trp Ser Pro Glu Ala Met Gly Thr Pro Trp Thr Glu Ser Arg Ser Pro Pro Ala Glu Asn Glu Val Ser Thr Pr~o Met Gln Ala Leu Thr Thr Asn Lys Asp Asp Asp Asn Ile Leu. (C-terminal) A 4 DNA coding for the protein defined in

8. claim 1. I I’ 41

9. AADNA coding for the protein defined in claim 2. A DNA according to claim 9, wherein said DNA has the following nucleotide sequence (5’1 -termninal ATG CTG GCC CTG CTG GCC AGG CGC TGC GTG CTG ACC CTG ACC TGC GCC ACT GTT GCA GGC. TCC GTC GGC TGC GCG CTG GCG CCG GGA 0 0a n o 0 00 0 400 000 0 a a aa a 0 00 GGA AGG CAC GAC GGC CGC GAT GTT TTC CGG GAG TGG ACA AAG AAC AGT CAG TAT CAG TTA TAC ATA GGG AGC GGT TGT AAC ATC CGC TGG TO” TGG GAG CTC TTC ACA CAC TGT AGG CAC TTC GGG GAG GCO AGT COT ATG CAG AGG TCT CCA CCC AAG GGT GCT CCG TOO GCA GTG AAG GGA ACA CTC AAC AGA ACA GTO GTG CAA ATG OCA GCA OCT AGT CCG CAC CAC CTG GGA GCT CCC AGO OCT GTG GC CAG GTO TOO TTO ATO GTC AGT TCA TAT TGG ATO GTG GGC GGO GOT OTT GOG CTG GGG TGG CCC OTG AAC GGG GAG CCC CGG OTO GAA GAG CG ATG AGO TTG ACT GTO TOT OGG ATG CAC CAG GAG AOG GAG ACT CAG OCA GTA GTG AGO OTG TAT ACT GAG OTO AGO TTG GAO, TOO GAG TGO AAA CAG GC ACC TTO GOT GTO GAC CTT TGG COT AAC ACT GOG GAG GGA GAG OTO AGA AGG TOA GTG CCC AGO ACC GTG TTO CAG GGA GTC ACT OCT GTG TGG TAO GAA AAG GC OGT AGO TGG GAG AAT GOG GTG GAO CG AGG TGG TCG TGO CAC CAG AAT OCA AGG CAG AAG GAO GC CAA GAT GCC CAA AGA CGG GAO TGG GC GAG ACA GTG AAA OTG CTG GCA AGO GAA AAG GOT GTG TAO TTG OTO GTT TOO AAG GAG TTO AGO AGT COG AGA GAO OTA TCA OTO AGO CAG TGG GAA TOO GAO GOT GC AGA GTG GAO CG GGO CAG OGG CTG TOO GTT CTG TTT COG TOO TOT AGT TTT COT AAO COO CGG AAG CAG GGO GAG AGO TOO ACC GAT GC OCA GGC ACT AAT GOT ATG CTO GC GTG TGC TGT AOG CAG TGC TGC TTO GTC CAG GC COO CAC TTT ACA CAT CTG GAG CG AGG CCC GAT 00 oo o a a 0 a 00 a a a a a 00 AAT ATT OTO TTC AGA GAT TOT GCA AAT GCG ACA LiT6 I I -1 A VL–.-A 42 AGC CTC CCA GTG CAA GAT TCT TCT TCA GTA CCA CTG CCC ACA TTC CTG GTT GCT GGA GGG AGC CTG GCC TTC GGA ACG CTC CTC TGC ATT GCC ATT GTT CTG AGG TTC AAG AAG ACG TGG AAG CTG CGG GCT CTG AAG GAA GGC AAG ACA AGC ATG CAT CCG CCG TAC TCT TTG GGG CAG CTG GTC CCG GAG AGG CCT CGA CCC ACC CCA GTG CTT GTT CCT CTC ATC TCC CCA CCG GTG TCC CCC AGC AGC CTG GGG TCT GAC ATT ACC TCG AGC CAC AAC CGA CCA GAT GCC AGG GAC CCA CGG AGC CCT TAT GAC ATC AGC AAT ACA GAC TAC TTC TTC CCC AGA. (3′-terminal) °oo’ 11. A DNA coding for a protein according to any one of claims 3 to 7. 15 12. A DNA according to claim 8, wherein the DNA is oo”, operatively linked to other DNA sequences which regulate Sa the expression of the former DNA.

13. An expression vector continuing DNA coding for receptor protein for human B cell stimulatory factor-2, o, 20 capable of specifically binding to the human B cell o o stimulatory factor-2.

14. A host organism transformed with expression vector according to claim 13. A process for production of a receptor protein for human B cell stimulatory factor-2, capable of 0″ *Q specifically binding the human B cell stimulatory 0 factor-2, comprising culturing the host organism according to claim /4-in a medium to produce the receptor protein and recovering the receptor protein from the culture.

16. An antibody capable of specifically reacting with a protein according to any one of claim 1 to 7.

17. Hybridoma capable of producing an antibody according to claim 16. -1 -I r 43j 43

18. An isolated receptor protein according to any one of claims 1 to 7 substantially as hereinbefore described.

19. A DNA molecule according to any one of claims 8 to 12 substantially as hereinbefore described. An expression vector containing DNA coding for receptor protein for human B cell stimulatory factor-2, capable of specifically binding to the human B cell stimulatroy factor-2.

21. An expression vector according to any one of claims 13 or 20 substantially as hereinbefore described.

22. A process according to claim 15 substantially as hereinbefore described.

23. A monoclonal antibody capable of specifically 4 reacting with a protein according to any one of claims 1 to o 7.

24. A monoclonal or polyclonal antibody according to claim 16 or claim 23 substantially as hereinbefore described. A hybridoma cell line capable of producing an antibody according to any one of claims 16 or 24.

26. A hybridoma cell line and hybridoma according to any one of claims 17 or 25 substantially as hereinbefore described.

27. Plasmid pA BSF2RI.1 as herein defined with particular reference to example 6.

28. Plasmid pABSF2RII.5 as herein defined with particular reference to example 7.

29. Plasmid pSVL324 as herein defined with particular reference to example Plasmid pSVL345 as herein defined with particular reference to example DATED this 22 July 1991 CARTER SMITH BEADLE Fellows Institute of Patent Attorneys of Australia Patent Attorneys for the Applicant: A 4 TADAMITSU KISHIMOTO 9, 12~ Fig. I L 4 4 0 99 9 99 99 *99 99 9 9 9 99 99 9 9 4 9 99 1%9 0 a 9 I, U 9 9 9 0 0. 10 100I INTENSITY OF F’LUORESCENCE o 40. 0 0 440 4 4 0 a 4 444 2 Fig. Pst I PvuT[ Sinal Sphi Smal PVUII Bat! EcoRV Pvufl SphI X hoI a aa a a aaa a a a a C C Fig. 3-I/ i na 1) TCATG”G-CGAGTC(C t CTCGCACTC-‘CACT”-AGCCGGC-CCA’GACGGA:;G GGAGCCGAGC AT’G CAC Leu CTG Cvs TGC pro: CCcG Pro ccc Ala GCC Prc CCT Ser AGC VA, I GTC Ala CGCG va I Ara AGA CAG& Gltu TGG C–S TGC G Iu GAG Pro 3l.a GCG ,v GTG G I u GAA7 Leu 2Ila A a Leu GCT G CC C T G Ala GCA AGA Asrn .Z Pi GGC !Leu ACC Ala t3cc SI-fr Ala Prn G c O c c IS Leu CTG Va I t’T47 A-ra A C G i 11 G Pr:- CCA L eu CTC1 Ser TC I_- SGAC mrcr lvs G JAG Se r CCG Lee CTC Lee CTG Va 1. GTG Ala GCT His CAC GCC Thr Ala -CA GAC Pro Leu CTG G lv GGC Ser TCT Thr (J1 Ser TO’ Ala GCT -elt ATCG ,Zl cTt– 0 *OQ 0 0 0 0 000 0 0 0 4 0 00 0 0 C 0 0 0 00 0 0 0 a ~0 0 00 0 40 @4000 000 0 Fig- 3-2 ;z7.a GkyTh C- i GCT cvtkl A.CT 4T; r G t u 7– Ser G~rn Pro civs Letu CwC S er (7vs CAG TAT’ ‘C2C~ P~e Arg L’:s CCIA :-feu ‘311 Ser AG-4 4 C~0 1. 77f I C’ I u s– Va i GTT G Iv ~GGT Pro ccc Pro CCT Pro ccc Arcr- CG AS GLAL GluG AC CAG GAGn Cys T C C Let: SCT TT T CA i KS rci’ ZI a e-‘Cc f-7- -as T :~Ala Val ‘Pro C-lu AA” T4 0 lrn4 r C T G*00 fl’ GAGl 3GA 7-A ~r ~te 5~r Vi. ~!’et2ar .xs r Cint T!hr 4, WIS’0 44C, r 0 C 40 0C 0 05 7C,~5 4 0 o SC 0 4 C p 00 000 0 0 0 0 0 0 o 00 000 0 00 Fig- 3-3 n Gl(7 0 Ue IL Pro GA, Lea Arc- A ,A .a Ir Ue Grc AWl T~r E~ S ler -ocr, ~00 .~La C2t~ ~rr- CCC Rc ser As-, 17AT £rc rr~ ~0f0 ~0~flfl ~0~-0 V70~ ‘rh’ ‘7a hrAla ‘Val AlI-r sn AC-. G- T4T CCC GTG CCC AG’ A;?C r P hfs <0757 sn GAC T,.,r ILeu CTC Leu CTA GIn CAG Giu GAG Arcv CAT Phe TTC TTT HC A K Asr> GAC rzCc C-r rci Z, 7 rcr Gin GCi, AGGAG cl- C~ G7 Gi ‘2r ~e Gu ~’r~~3er~rr Gt~ o Tr Th zt~rArf SerPr r p00 (0 ~0f~y 0~ -o~0 00~0(G CC-~~j C~T CA AA TCC AGG ACT CCT CCA I p 000 PC P P PP app p Pa P 0 a p* Fig. 3- 4 Ala Glu GCT GAG Arg Asp AGA GAT Asn Gin ‘.al Ser Thr Pro M4et Gin Ala Len Thr Thr Asn Lys Asp Asp Asp Asn Ile Leu Phe AAC GAG G-TG TCC ACC CCC Ar7G CAG GCA CTT7 ACT A7CT AAT AAA GAC GAT GAT AAT ATT CT-C TTC Ser Ala Asr. Ala Thr Ser Len Pro Val G-n PoSer Ser Scer Val Pro Lpu Pr-o Thr Phe Leu TCT AAT PCA AGC CTC CCA GTG CAA GA? tT TCT TCA: (‘CA CTG CCC ACA TTC CTG G~) Val Ala Gl: Glv Ser Len Phe Glv. Thr Lou e M.a TIe Vo’l Teu Arq Phe Lys Lys Thr GTT GCT GGA GGG AGC CTC rzCC TTC GCA ACC CT,- CTC Tt-Ci -A’T GCC A TT G’TT CTG AGG TTC AAG A; AG ACG Trp Lys TGG AAG Pro Gin CCG GAG Len Arc’ Ala Len -1,ys Glu Glv Ly;s -hr Met H!-s Pro Pro Ty’r Ser Len Gly Gin Len Val CTG CGG GCT CTG AAG GAA GGC AA- ACA IiCC ATC, i’AT CCC CCG- TAC TCT TTG GGG CAG CTG GTC Arg Pro Arq Pro Thr Prn Val Let: Fa rc; Leu Ser Pro Pro “.al Ser Pro Ser Ser Leu AG-G OCT CA CCC ACC CCA CTT T CT: ATC TCC (‘CA CCG GTG TCC CCC AGC AGC CTG Fig. Gly Ser Asp t-sn Thr Ser Ser His A~n Prcf Pro, zAsp Ala Arg Asp~ Pro ?~rq Ser Fro Tyr Asp Ile Ser G CT kT ,AC AAT C TZG AGO- CAC AAC C-A, CCA GAT’ GCC AGG Gc-AC CC-A CCG ZAC- CCT TAT C-AC ATC AGC (C-Terrta7-) Asn Thr Ty~r Phe Phe Pro Arcr -AA~r ACA G.AC T.AC T C’ T c CCC C. N TACGGr TCCTTC TC.AC’GCCATGCCAGCCTT (3 TTAG-TA %CCCT GACTCTTTG GACCTCCACGAACTAAAc-TGGCAG~2T-(T~G~ C-t-,CAGC -C-;!CCCCTCA-:CACC,-CTGC-ACA JAGCTCTG(3′-Ter–.inal) 4-, I OD OD CD, CD, I1 aS 4 a S 4 a a a 54 a.. a a a S S a 5 *S a. St C ZN I U1266 SHORT EXPOSURE U937 721 U 266 co -4 46 CGE SS B3 L29 d) Jurkat YT p Fi1g. SIGNAL PEPTIDE Xhol Mrol HindUl S spl PROMOTER >(hol Pstt. MPBSF Pst.CV PIEA S sPLtCEt’An PROMOTER POLY An (POLY A SIGNAL)(PLA SupF COMS8 SIGNAL) HindIII/Mrol SspI 1 n yo f Xhor (M rot) S tp1 Pstl Lc Lzzz, SIGNAL PEPTIDE DNA LIGASE SIGNAL PEPTIDE Xhol (Mro/Sspl) CMV* PROMOTER ~p,5BSF2RI-1 Pst r SPLICE A n (POLY A SIGNAL) 10/25 Fig SLGNAL PEPTIDE *Fspl o #0 0 0 a a 0 .,04 0 o ~o aO a o 00 0 40 0 0 X ho I FspI Xhol pstE 6 PstL E \X bal.C SPLICE±An SPLICE+An PiOTR(POLY A “(FoL A S[GNAL) SIGNAL) ApOL/Xbal SupF 1CDM8 P r MUNG BEEN M13 on P o NUCLEASE ton SVoi PstI Voi V0r (DNA FRAGMENT Ejt (Apg4l) stE (DNA FRAGMENT F >Xhot FspI 6ff:1 SIGNAL PEPTIC, IDNA LIGASE SIGNAL PEPT[DE Xhol (FspI /A pa L1) CMV he PROMTER pABSF2Ra6~ PstI. SPLICE4 An (POLY A SIGNAL) 0* 0. 0 0 00 0 a 00 U- 11/25 Fig. 0 8C 6C 2C 0 0 0 0 0* 0 eO C) 01 INTENsrTY 10 0OF 100 FLUORESCENCE ‘2/2 Fi g, 8 4 4, 4 *4*4 44 4 4, 6~ o 44 4 4 444 44 *4 4 44 44 4 4 4 .4 4 4 4* 4 4 4 44 44*444 4 4 4 0 4 0 0.1 1 10 100 INTENSITY OF FLUORESCEC.NCE A 13/25 Fi g. 000 0 0 0000 0 o 00 0 00 0 00 0 00 0 0 a* 00 0 0 L 0.1 1 INTENSITY 10 100 OF FLUORESCENCE 14V Fig. /0 (A) SphI 0000 0 0 000 0 0 0 00 Sphi FRAGMENT ~~Sph[Sphl INSERTION TO Sphl OF mpIS *SalI Sph]I HindII Sp hi CLEAVAGE .SphI “”~Sall INTRODUCTION OF TAG BY SITE SPECIFIC MUTAGENESrS Sp h t ‘Sall i TO F1 j12 (8) 15/25 Fig. /0(8) FROM Fig,12(A) 4,4 44 4 4 44 .4 4 4 44 4 *4 CLEAVAGE Hindlil Salt TAG OpECE 8a~mHl CLEAVAGE Sal I amHt i3-GLOBLN polyA CONTAI NING HUMAN/3-ACT ION PROMOTER IN pUC9 Hindli 8QmHli CLEAVAGE Hind Il HUMAN f,9ACT1N PROMOTER Ba.mHt Puc 4444 4 44 4 4 4 44 4 4 4 6 4 4444 4 4 4 44 44 14 4 4 I 44 6 4 4 4 4 44 HUMAN 3 -ACTIN PROMOTrER 03 0 0 0 0 0 0 0 030 000 0 00 0 03 Fig.!! BOUND 125 BSF2(cpm 1000 2000 NO. I ~DMEM-i–O% FCS 2 SUPERNATANT OF L CELLS SUPERNATANT OF 3 L CELLS TRANSFECTED WITH ph)3ABSF2R 4 NO.3± 2O0ng/m BSF2 K~’1 01 N -1 V725 S phlt CMV MOTER Fig.!?2 Sphl 8mpi8 Smet L LtXbai XcyI Secl BamHll VP1 .INTRQN SV’10 LATE SV 40 POLY A LATE DEN YLATION PROMOTER (pSVL v SV4O’Q 48b~ or i PBR322 ort T A PC 066 0 0 0 *Go 00 160 I Sphl Sphl Sp SphI., SphI. hr SAP DNA FRAGMENT A~j jXhol/BaMHI IDN GIASE IL/INMA L iU;Azc Xhol, SFpJ SITE aH PR.C N o OLY A SYTHrt~ SV40LJ pSVL34!5 SIGNAL I -ATATTCTAGcAGATT3’o I C*;NfTATION SIT ArpR ENrRODUCTIQN OF TAG BY SITE-DIRECTED IN VITRO MUTAGENESIS nhor Sphl A BarnHt SphI $pht SphI SphI Sphl Split TA1_41111. BAP I-ONA LIGASE Sph I X1101-Sphl jXhol/8 omHI Xh oI’ am1 (DNA F’RAGMENT TAG 1825 Fig. 13 SIGNAL PEPTIDE Sphl Sh Sine Xcyl Seci BamHI SphI ISphl Spht Sph I BAP (DNA FRA3-MENT EB) I Xhol/BalmHI BA P DNA LIGASE *4 I ~~II I I 00 I 4* 0 4 I *0 Sphl, SPFLICI NG Sphl SITE BclmHI SPOLY A SYNTHETIC SV4OLf pSV324 SIGNAL OLIGONUCLEOTIDE orl 5LGTrCCTCCG T’4 TAGAACGAGGT-3 I I(*,.MUTATION SITE) AmpR INTRODUCTION OF TAG BY SITE- DIRECTED EN VITRO MUTAGENESLS ThiSphl -4<-BcimHf SphI, 44 40 0 I~ 4 4* ISphE Sphl BAP TAG tDNA LIGASE SphI Xho I ZZ'G pSP73 BwinHL (324) Xhor>Download PDF in English